Home » Stocks » XCUR

Exicure, Inc. (XCUR)

Stock Price: $2.31 USD 0.04 (1.76%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $2.35 +0.04 (1.73%) Jan 21, 7:44 PM
Market Cap 202.35M
Revenue (ttm) 16.78M
Net Income (ttm) -21.96M
Shares Out 87.23M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $2.31
Previous Close $2.27
Change ($) 0.04
Change (%) 1.76%
Day's Open 2.35
Day's Range 2.22 - 2.38
Day's Volume 343,847
52-Week Range 1.03 - 3.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that the U.S. FDA has granted Fast Track designations for cavrotolimod (AST-008) for two development programs.

Business Wire - 2 weeks ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced the appointment of James Sulat to its Board of Directors.

Business Wire - 2 weeks ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual R&D Day on Thursday, January 7, 2021 from 09:00 am to 10:30 am ET to discuss Exicure's neuroscience pipeline.

Business Wire - 3 weeks ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021.

Business Wire - 3 weeks ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that it will host a virtual R&D Day on January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure's neuroscience pipeline.

Business Wire - 1 month ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced that the U.S. Patent and Trademark Office has issued two new patents and allowed U.S. patent application 14/907,430.

Business Wire - 2 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. will participate in the 2020 Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day and the Virtual Fall Investor Summit.

Business Wire - 2 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. today reported third quarter 2020 financial results and corporate progress.

Business Wire - 2 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure presents positive clinical data with cavrotolimod at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.

Business Wire - 3 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced an upcoming poster presentation for cavrotolimod (AST-008), at the 35th Anniversary Annual Meeting of SITC.

Business Wire - 3 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced a presentation at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020.

Business Wire - 3 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced it has entered into a $25.0 million senior secured term loan with MidCap Financial Trust and Silicon Valley Bank.

Business Wire - 4 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual Key Opinion Leader (KOL) event to present preliminary Phase 1b efficacy and safety data.

Business Wire - 4 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced presentations at two upcoming conferences during the month of September.

Business Wire - 4 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual KOL meeting on September 16th, 2020 to discuss the preliminary Phase 1b efficacy and safety data for cavrotolimod.

Business Wire - 5 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today reported financial results for the quarter and six months ended June 30, 2020 and provided an update on corporate progress.

Business Wire - 5 months ago

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced that David Giljohann, CEO, will present a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020.

Market Watch - 1 year ago

Shares of Exicure Inc. XCUR, +3.46% gained 6% in premarket trading after it said that it will start enrolling patients in a Phase 2 trial for the biotech's experimental immuno-oncology drug.

Benzinga - 1 year ago

Shares of the thinly traded micro-cap Exicure Inc (NASDAQ: XCUR) were advancing strongly Thursday in the wake of a collaboration agreement announced by the company with Allergan plc (NYSE: AGN).

Other stocks mentioned: AGN
Market Watch - 1 year ago

Shares of Exicure XCUR, -4.65% are up 26% in premarket trading on the news that the biotechnology company entered into an agreement with Allergan AGN, -0.20% to develop treatments for hair los...

About XCUR

Exicure, a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interl... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
David Giljohann
Employees
57
Stock Exchange
NASDAQ
Ticker Symbol
XCUR
Full Company Profile

Financial Performance

In 2019, Exicure's revenue was $1.30 million, an increase of 998.31% compared to the previous year's $118,000. Losses were -$26.30 million, 17.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Exicure stock is "Strong Buy." The 12-month stock price forecast is 10.00, which is an increase of 332.90% from the latest price.

Price Target
$10.00
(332.90% upside)
Analyst Consensus: Strong Buy